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ABSTRACT
Objective: To evaluate the safety and efficacy of Viva QS®, an herbal medication consists of a combination of twelve herbs
for smoking cessation in Malaysian adult smokers. 
Methods: A randomized, double-blind placebo-controlled study was conducted in the industrial factories in Kerteh and
Kuantan, Malaysia. The subjects were recruited from those attended mobile smoking cessation programme (MSCP), agreed to
sign written consent and fulfilled study criteria. Demographic and smoking history information, modified Fagerstrom test for
nicotine dependence (FTND) score and carbon monoxide (CO) level were obtained at baseline. Follow-up was conducted by
phone calls and/or face-to-face meetings at three time points. Viva QS® and placebo were supplied for 24 weeks. 
Results: One hundred and fifty-five subjects were randomized from 1st April 2008 to 26th October 2008 in the study.
Biochemically verified 7-days point prevalence demonstrated Viva QS® significantly increased quit rate vs. placebo; 42.7% vs.
26.2% (p = 0.038) at week 4, 32.0% vs. 16.7% (p = 0.031) at week 12 and 30.7% vs. 13.9% (p = 0.015) at week 24. Adverse events
reported were similar between groups. The most frequently reported adverse events were sore throat and dry mouth (36.6%
and 17.8%, respectively for Viva QS® vs. 28.8% and 16.9% for placebo). 
Conclusions: Viva QS is safe and effective to aid smokers quit smoking in this population sample.
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Addiction to nicotine is so strong that alcoholics and drug addicts
asserted it would be less painful to quit these substances, as com-
pared to nicotine1). In 2006, according to the Third National Health
and Morbidity Survey (NHMS3) carried out by the Ministry of
Health, Malaysia in 2006 found out that 27% of the population are
ever smokers, 21.5% are current smokers and only 5.4% were catego-
rized as ex-smokers2). It was also reported that 70.6% of current
smokers attempted to quit and on average, smokers had 2.1 times quit
attempts in the past one year.
The search for new alternative treatments or interventions for
smoking cessation remains an area of research agenda. Herbal med-
ications have been used long time ago as alternative interventions, in
addition to the current pharmacological treatment available. We con-
ducted a study to assess the efficacy and safety of an herbal medica-
tion namely Viva QS® as an alternative intervention for smoking
cessation. Viva QS® is consisted of twelve herbs mainly found in
Korea and China. It was originally developed from Viva®, a medica-
tion used in suppressing opiate withdrawal symptoms and acted as
therapeutic nutrient to detoxify drug addiction3). Through observation
during the treatment, patients also admitted distaste to cigarettes, thus
Viva QS® was developed for the purpose of smoking cessation, but
some adjustments were done in the amount of certain herbs, as in
Table 1. 
MATERIAL  AND  METHODS
Study design
This study was a randomized, double-blind placebo-controlled trial
of 155 industrial-worker smokers. Study was conducted at 11 industrial
workplaces in Kerteh and Kuantan, Malaysia. Subjects were selected
conveniently from those attended mobile smoking cessation pro-
gramme (MSCP), handled by a team consisted of pharmacists and fam-
ily medicine specialists. MSCP was conducted to assist hard-to-reach
smokers to help them quit smoking. Recruitment was promoted by
emphasizing the importance of smoking cessation and the opportunity
to participate in the study. Each subject was given a set of self-admin-
istered demographic and smoking history questionnaires, and an
informed consent to read through. Smokers who agreed to quit and to
sign the consent form were screened for eligibility and those fulfilled
the inclusion and exclusion criteria were selected for enrolment. 
Screening
Subjects were screened for inclusion and exclusion criteria.
Nicotine dependence level was assessed using the modified FTND
test. Upon signing the informed consent form, eligible subjects filled
in the given questionnaires. Baseline smoking status was determined
by measuring the level of carbon monoxide (CO) using PiCO+
Smokerlyzer in an exhaled air sample. The peak expiratory flow rate
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(PEFR) was obtained using peak flow meter. Each subject was given
a booklet, contained a form to record the daily cigarette smoked, if
any, from the date of commencement until the end of week-24, and a
withdrawal symptoms score sheets, modified based on the revised
Nicotine Withdrawal Scale (MNSW-R)4) to record any withdrawal
symptom from week 1 until week 5. Subjects were required to select
a ‘target quit date’ to quit smoking. 
Inclusion criteria
1. Male smokers age 18 to 60 years old.
2. Subjects should be able to speak English or Malay.
3. Fagerström score test is 4 or more.
4. Give consent to be involve in the study.
Exclusion criteria
1. History of dependence on alcohol or drug abuse within the past
year.
2. Current or past history of medical treatment on these chronic 
diseases, i.e. asthma, any cardiovascular disease, HIV or 
AIDS, cancer, mental disorders and serious liver or renal dis-
ease or history of transplantation.
3. Current used of nicotine replacement therapy or bupropion SR.
4. Drinking more than 8 cups of coffee per day (75 ml each cup).
Randomization
Subjects satisfied the study criteria were randomly assigned to
receive a 24-week supply of Viva QS® or placebo. Subjects were
randomized between April 1, 2008, and October 26, 2008, with the
last 6-month follow-up session completed in May 17, 2009. The man-
ufacturer was responsible for the randomization; the medication
packs were numbered from 1 to 155. Subjects were assigned to a spe-
cific treatment number based on the provided randomization code.
There was no difference between placebo and Viva QS® in appear-
ance, color and shape of the capsules, and were packaged in identical
blisters packaging and boxes. Viva QS® used was from the same pro-
duction batch. The administration of the capsules was conducted on a
double-blind basis i.e. all subjects and the researchers had no infor-
mation on who received Viva QS® or placebo. 
Treatment and follow-up period
The duration for this period was 24 weeks (Figure 1). The manu-
facturer fixed the dosing regimen as shown in Table 1. Compliance
was assessed based on self-reporting and capsules counting. Subjects
were instructed to quit smoking on their target-quit date; we suggest-
ed on the eighth day after they consumed the medication. At week 2
subjects were contacted by telephone call to obtain the quit date. At
week 4 subjects were follow-up by telephone calls to assess smoking
status and adverse events experienced by subjects at that time point.
Subjects received brief counseling of 5-10 minutes during the follow-
up. One same researcher was responsible to perform all counseling
and follow-up by telephone. Subjects were continuously contacted
until reachable; if the subjects were still unreachable at this time
point, subjects were included as missing in the analysis.
At week 12, subjects were met individually face-to-face at their
workplaces or at an organized meeting location. At this time point,
three researchers were involved to provide individual brief counsel-
ing session (5-10 minutes) as well as assessing the smoking status. In
order to avoid biases and variability in the follow-up reports, a stan-
dard follow-up form was used. Smoking status was assessed by self-
report and confirmed with CO test; and smoking abstinence was con-
firmed by expired CO levels < 8 ppm5).
At this time point, subjects who were unable to be follow-up
face-to-face, were contacted by telephone calls. Abstinence was
recorded according to self-report; self-reported smoking status alone
was accepted to be documented, even without validation with CO
test. At this time point, CO test was not compulsory, thus follow up
via telephone calls or face-to-face were both accepted. Adverse
events were documented according to self-reports from the subjects,
thus, there was no difference in terms of documenting the adverse
effects; either by face-to-face or telephone call as no physical exami-
nation was conducted in the assessment.
Study completion
Subjects completed the treatment period at the end of week 24.
Researchers met the subjects again at the workplaces or at an orga-
nized meeting location for this final visit. In addition to self-reported
smoking status, validation of abstinence at the end of study was con-
ducted using CO test and measurement of cotinine in urine and/or
saliva. Subjects who were unable to be met at this point were follow-
up by telephone calls or by contacting the medical personnel in-
charge at the workplaces to confirm the smoking status but subjects
without biochemical markers validation were considered smokers. 
Biochemical validation
Carbon monoxide (CO) measurement was taken at week 12 and
week 24. At the end of study, cotinine level was obtained by measuring
samples from urine and/or saliva of the subjects, regardless of their self-
reported smoking status. For cotinine level in urine sample, cut-off point
of 50 ng/ml6) was applied to differentiate a smoker from a non-smoker,
while a cut-off value of 8 ppm5) was applied for the CO monitoring. For
saliva NicAlert®, a cut-off value of 1 (presenting 10-30 ng/ml) was
used6), meaning the actual cut-off value considered is 10 ng/ml.
Biochemical instruments for validation
1. Pico+ Smokerlyzer was used to measure carbon monoxide (CO) 
level in an exhaled air sample.
2. Saliva NicAlert® was used to measure cotinine level in saliva 
samples. 
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Figure 1. Flowchart of Subjects’ Recruitment and Follow-up
Table 1. Dosage of Study Medication
Treatment week Dosage (Viva QS® / placebo)
Week 1 2 capsules 2 times per day (2 BD)
Week 2 and week 3 1 capsule 2 times per day (1 BD
Week 4 to week 24 1 capsule once a day (1 OD)
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Table 2. Baseline Demographic Characteristics
Characteristics Viva QS® Placebo Total p value
(n = 75) (n = 72) (n = 147) (2-tailed)
Age (years), n (%)
18-30 24 (32.0) 28 (38.9) 52 (35.4) 0.594
31-45 37 (49.3) 34 (47.2) 71 (48.3)
46-60 14 (18.7) 10 (13.9) 24 (16.3)
Race, n (%)
Malay 74 (98.7) 71 (98.6) 145 (98.6) 0.741
Others 1 (1.3) 1 (1.4) 2 (1.4)
Marital status, n (%) a
Married 63 (86.3) 62 (87.3) 125 (86.8) 0.856
Never married or divorced 10 (13.7) 9 (12.7) 19 (13.2)
Education, n (%)
Secondary school 16 (21.3) 26 (36.1) 42 (28.6) 0.116
Certificate 10 (13.3) 10 (13.9) 20 (13.6)
Degree/ Diploma 49 (65.3) 36 (50.0) 85 (57.8)
Employment, n (%)
Management 17 (22.7) 14 (19.4) 31 (21.1) 0.632
Technical 58 (77.3) 58 (80.6) 116 (78.9)
Age begin smoking (years), n (%)
10-15 22 (29.3) 19 (26.4) 41 (27.9) 0.692
16-20 42 (56.0) 45 (62.5) 87 (59.2)
21-40 11 (14.7) 8 (11.1) 19 (12.9)
Baseline tobacco use (No. of cigarette smoked per day), n (%)
1-10 sticks 19 (25.3) 16 (22.2) 35 (23.8) 0.216
11-20 sticks 42 (56.0) 49 (68.1) 91 (61.9)
> 20 sticks 14 (18.7) 7 (9.7) 21 (14.3)
Baseline Fagerstrom test score for nicotine dependence, n (%)
4-6 61(52.6) 55 (47.4) 116 (78.9) 0.463
7-10 14 (45.2) 17 (54.8) 31 (21.1)
Mean carbon monoxide (CO) level (ppm), (SD) 11.63 (4.834) 11.38 (4.294) 11.50 (4.564) 0.739
Mean Fagerstrom test score for nicotine dependence, (SD) 4.91 (1.317) 5.15 (1.469) 5.03 (1.394) 0.286
a n = 144. Three subjects with missing data.
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Table 3. Baseline Tobacco Used Characteristics
Characteristics Viva QS® Placebo Total p value
(n = 75) (n = 72) (n = 147) (2-tailed)
Previous cessation attempted, n (%)a 64 (85.3) 61 (84.7) 125 (85.0) 0.917
Duration of quitting (years), n (%)a
< 1 57 (89.1) 51 (83.6) 108 (86.4) 0.374
1-3 7 (10.9) 10 (16.4) 17 (13.6)
Reasons for previous relapse, n (%)a
Difficulty in concentration 32 (50.0) 37 (60.7) 69 (55.2) 0.231
Craving for cigarette 38 (59.4) 25 (41.0) 63 (50.4) 0.040*
Impatience 21 (32.8) 22 (36.1) 43 (34.4) 0.702
Frustration and uncontrolled anger 20 (31.3) 22 (36.1) 42 (33.6) 0.569
Bad temper 14 (21.9) 18 (29.5) 32 (25.6) 0.328
Insomnia 16 (25.0) 14 (23.0) 30 (24.0) 0.789
Increased appetite 10 (15.6) 13 (21.3) 23 (18.4) 0.412
Influence by friends 10 (15.6) 8 (13.1) 18 (14.4) 0.689
Awakening at night 6 (9.4) 8 (13.1) 14 (11.2) 0.508
Depression 6 (9.4) 3 (4.9) 9 (7.2) 0.493**
Reasons for current quit attempt, n (%)
Health 67 (89.3) 61 (84.7) 128 (87.1) 0.405
Family, friends and loved ones 52 (69.3) 46 (63.9) 98 (66.7) 0.484
Economy 30 (40.0) 36 (50.0) 66 (44.9) 0.223
Job requirement 8 (10.7) 6 (8.3) 14 (9.5) 0.630
Religion 5 (6.7) 2 (2.8) 7 (4.8) 0.268
a n = 125 (22 subjects had never attempted to quit prior to the study).
*p < 0.05
** Fischer’s exact test.
191Zaswiza M. N. et al.
Table 4. Biochemically Verified 7-Days Point-prevalence Abstinence Rate at Week 24 
Viva QS® Placebo OR p value
(n = 75) (n = 72) (95% CI) (2-tailed)
Total quitters, n (%) 23 (30.7) 10 (13.9) 2.74 (1.20-6.28) 0.015
Verified abstinence by saliva cotinine test (ng/ml),  n (%) a, d 13/27 (48.1) 10/27 (37.0)
Verified abstinence by urine cotinine test (ng/ml), n (%) b 10/13 (76.9) 0/7 (0.0)
Verified abstinence by carbon monoxide (CO) test (ppm), n (%) c 30/41 (73.2) 21/34 (61.8)
a Scale (ng/ml): 0 = 1-10,  1 = 10-30,  2 = 30-100,  3 = 100-200,  4 = 200-500,  5 = 500-2000.
b Scale (ng/ml): 0 = not detectable, 1 = 1-20, 2 = 20-50, 3 = 50-100, 4 = 100-200, 5 > 200
c Scale (ppm): 1 = 0 - 7, 2 = 8 - 10, 3 = 11 - 20, 4 > 20.
d Subjects (n = 54) provided urine samples as well for validation of cotinine level in urine. Samples were unable to be analyzed due to technical problem in the laboratory. Final 
analysis used saliva samples only for validation of cotinine level in these subjects.
3. High performance liquid chromatography with ultra-violet 
(HPLC-UV) detection to measure cotinine level in urine sam-
ples. This method was done in a laboratory based at the 
International Islamic University Malaysia.
Efficacy evaluation
Self-reported 7-days point prevalence tobacco7) and continuous absti-
nence rates8) at two time points were assessed for quit rates measure-
ment. Primary dichotomous outcome or end-point is 7-days point preva-
lence at 6 months i.e. week 24. 7-days point prevalence at week 4 and
week 12; and continuous abstinence rates from week 4 through week 12
and week 4 through week 24 were evaluated as secondary outcomes. 
Self-reported non-quitting status or at the time when CO level
was 8 ppm or higher, or when saliva or urine cotinine test result was
higher than the cut-off values, subjects were considered smokers dur-
Table 6. Rates of Continuous Abstinence at Two Different Periods
Period of Continuous abstinence OR p
follow-up rates, n (%) (95% CI) value
Week 4 to
week 12 a




Viva QS® 19/75 (25.3) 2.38 (0.99-5.67) 0.048
Placebo 9/72 (12.5)
a n = 147 (subjects with missing data were analyzed as smokers during these two periods).
Table 7. Adverse Events According to Severity, by Treatment 
Groups
Adverse events Viva QS® (n = 73)a Placebo (n = 71)a p value *
n(%) n(%)
Sore throat 21 (28.8) 26 (36.6) 0.894
Dry mouth 13 (17.8) 13 (16.9) 0.625
Cough 8 (11.0) 6 (8.4) 0.321
Anxiety 6 (8.2) 2 (2.8) 0.116
Headache 4 (5.5) 4 (5.6) 0.889
Bloating 3 (4.1) 3 (4.2) 0.667
Stomach 2 (2.8) 5 (6.6) 0.371
disturbances
Rhinitis 2 (2.7) 2 (2.8) 0.543
Vomiting 2 (2.8) 0 (0.0) 0.182
a n = 144, 3 subjects with missing reports.
* No significant difference in both groups in all events (all p > 0.05).
Table 8. Differences in Withdrawal Symptoms Reported by
Subjects at Two Time Points
Withdrawal symptoms Difference in symptoms p value *
compared with 
placebo group (95% CI)
Viva QS®
Week 2
Craving for cigarettes -0.204 (-0.670 to 0.261) 0.387
Difficulty in concentration 0.273 (-0.132 to 0.677) 0.185
Increase appetite 0.125 (-0.342 to 0.592) 0.597
Depression -0.066 (-0.432 to 0.299) 0.720
Bad temper -0.144 (-0.511 to 0.223) 0.439
Impatience 0.239 (-0.139 to 0.616) 0.213
Insomnia -0.242 (-0.606 to 0.122) 0.191
Frustration and uncontrolled -0.222 (-0.542 to 0.099) 0.173
anger
Awakening at night -0.124 (-0.377 to 0.129) 0.333
Week 5
Craving for cigarettes -0.121 (-0.490 to 0.249) 0.519
Difficulty in concentration -0.063 (-0.298 to 0.171) 0.593
Increase appetite 0.046 (-0.270 to 0.362) 0.773
Depression -0.024 (-0.217 to 0.169) 0.807
Bad temper -0.060 (-0.202 to 0.081) 0.400
Impatience 0.033 (-0.140 to 0.206) 0.704
Insomnia -0.065 (-0.224 to 0.094) 0.420
Frustration and uncontrolled -0.105 (-0.240 to 0.030) 0.128
anger
Awakening at night -0.087 (-0.215 to 0.040) 0.178
* No significant difference in both groups in all events (all p > 0.05).
Table 5. 7-Days Point-prevalence Abstinence Rates at Two Time 
Points
No of week after 7-Days point-prevalence OR p
quit date abstinence rates, n (%) (95% CI) value
Week 4 (n = 147)
Viva QS® 32 (42.7) 2.08 0.038 
(1.035-4.163)
Placebo 19 (26.2)
Week 12 (n = 147)
Viva QS® 24 (32.0) 2.35 0.031 
(1.071-5.169)
Placebo 12 (16.7)
Note. At week 12, 29 subjects were follow-up face-to-face and smoking status were con-
firmed and validated with CO test, whereas 111 subjects were follow-up by telephone call to
confirm the smoking status but without CO test for validation.
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ing treatment and follow-up period. In the case of continuous absti-
nent end-points missed visit or follow-up: if at the next visit or fol-
low-up there was a self-report of no smoking, a status of not smoking
was applied for the missed session9). Subjects who considered them-
selves smokers at week 4, week 12 and week 24, data was collected
on the number of cigarettes smoked and their current smoking behav-
iors, in addition to CO and cotinine samples. Subjects with missed
CO value but met other abstinence criteria, and provided self-report-
ed non-smoking status, were considered as non-smokers at week 4
and week 12. At week 24, this condition was not applied as non-
smoking status should be confirmed with biochemical markers. 
Safety evaluation
Adverse events were assessed according to subjects’ self-reported
and were not through observation by researchers. Any serious
adverse effects experienced by subjects or any case of hospitalization
either due to intervention or not, were documented and reported to
the manufacturer.
STATISTICAL  METHODS
Analysis of the data was done using SPSS version 12.0 for win-
dows. Cross-tabulation and comparison of means were used to summa-
rize baseline demographic data and baseline tobacco use. The chi-
square test and comparison of means were used to compare treatments
on primary and secondary end-points. Types of adverse events over the
entire period were compared between groups using cross-tabulation
and independent t-test. Comparison of means was used to analyze
mean in both groups. The test was considered significant if p < 0.05.
RESULTS
Baseline demographic and tobacco use characteristics
There were no significant differences in the baseline characteris-
tics of participants between treatment groups (Table 2). The average
age of the subjects was 35.2±8.36. On average, baseline Fagerstrom
test score for nicotine dependence (FTND) was 5.03±1.39. On aver-
age, the subjects started smoking at the age of 17.7±3.35. Table 3
showed tobacco used characteristics at baseline. The most commonly
reported motivational factors for current quitting attempt were health
(87%), family, friends and their loved ones (67%) and economy
(45%). The most common reasons for previous relapsed reported
among subjects were difficulty in concentration (55%), craving for
cigarettes (50%), impatience (34%) and, uncontrolled anger and frus-
tration (34%). 
Primary outcome
Abstinence rate at the end of study i.e. week 24 was assessed as
primary outcome. Self-reported abstinence at this time point was bio-
chemically validated by measuring cotinine level in saliva and/or
urine samples, in addition to self-report and CO test. Table 4 showed
the biochemically validated 7-days point-prevalence abstinence for
the treatment and control groups. The abstinence rate for Viva QS®
was significantly better than the placebo at the end of the treatment
period (30.7% vs. 13.9%; p < 0.05; OR, 2.74). 
Saliva samples (n = 54) and urine samples (n = 20) were man-
aged to be collected to measure cotinine level at the end of study. A
percentage of 42.6% (23/54) from saliva samples and 50% (10/20)
from urine samples demonstrated confirmed abstinence status. From
CO level measurement, results showed 68% (51/75) subjects were
confirmed abstinence, but 18 out of those 51 subjects showed dissim-
ilar results for saliva and urine tests. Thus, subjects were considered
smokers; as measurement of cotinine level in saliva and/or urine sam-
ple was the principal biochemical validation method. One subject
only agreed for CO test and refused to provide either saliva or urine
sample, thus he was classified as smoker. 
Secondary outcomes
The 7-days point-prevalence abstinence rates at week 4 and week
12 were assessed as secondary outcomes. The abstinence rates were
higher in Viva QS® as compared to placebo at all time points (Table
5). Results showed significant differences between groups; Viva
QS® vs. placebo (42.7% vs. 26.2%; p = 0.038; OR, 2.08) at week 4,
and (32.0% vs. 16.7%; p = 0.031; OR, 2.35) at week 12.
Continuous abstinence rates from week 4 through week 12, and
from week 4 through week 24 were assessed as secondary outcomes
(Table 6). Abstinence rates of Viva QS® were higher than placebo at
both periods. The continuous abstinence rate from week 4 through
week 12 differed significantly between treatment groups (Viva QS®:
29.3% vs. placebo: 15.3%; p = 0.041; OR, 2.30). Significantly, Viva
QS® showed higher abstinence rates than placebo from week 4
through week 24 (Viva QS®: 25.3% vs. placebo: 12.5%; p = 0.048;
OR, 2.38).
Measures of safety
54% subjects in Viva QS® group and 51% subjects in placebo
group reported at least one adverse event (p = 0.69). Adverse events
reported at any time of the study contact points throughout 24 weeks
of treatment period were similar between groups (Table 7). Sore
throat and dry mouth were the most commonly reported adverse
events in both groups (Viva QS®, 28.8% and 17.8%; placebo, 36.6%
and 16.9%). The least frequently reported adverse events in both
groups were rhinitis (Viva QS®, 2.7%; placebo, 2.8%) and vomiting
(Viva QS®, 2.8%; not reported in placebo group). Stomach distur-
bances showed lower incidents in Viva QS® (2.8%) as compared to
placebo (6.6%). 
Measures of withdrawal
Withdrawal symptoms were reported in 132 subjects (Viva QS®,
n = 69; placebo, n = 63); no withdrawal (n = 1) and not reported (n =
14). Table 8 showed no significant difference in withdrawal symp-
toms scores in both groups at all events at two time points. 
DISCUSSIONS
Majority of subjects in this study were aged 31 to 45 years
(49%), followed by group aged 18 to 30 years old (35%). Subjects
were randomly chosen from different group ages, to represent the
“real world” of adult population. Highest number of subjects was
group age 31 to 45 years as commonly at most workplaces, most
workers were about these ages.
In measuring efficacy in this study, we based respectively on the
ratio and the differences in the 7-days point prevalence abstinence
rates at three time points between groups, with the abstinence rate at
week 24 as primary outcome. Self-reported abstinence at week 24
required validations with biochemical markers, by measuring cotinine
level in saliva and/or urine samples, plus exhaled breath carbon
monoxide (CO) level. Secondary outcomes in this study were the 7-
days point prevalence abstinence rates at week 4 and week 12, and
continuous abstinence rates at two time frames.
Prior to commencement of the study, an abstinence rate of 21%
for intervention group and 16% for placebo were targeted. Results
obtained were different; with higher abstinence rates in intervention
group and lower in placebo. This study was the first randomized con-
trol trials (RCTs) conducted to assess the efficacy of Viva QS® for
smoking cessation and with limited studies involved herbal medica-
tions for smoking cessation, thus no standard reference were avail-
able. As a result, standard quit rates as in previous studies involved
NRTs, bupropion and varenicline were adopted.
It was common when smokers reported quitting “on their own”
through self-help either by “cold turkey”, or cutting down gradually
the number of cigarettes smoked, however, with the assistance of a
cessation programmes such as MSCP and pharmacotherapy, the quit
rates are usually higher on average, i.e. more than 20%. Intensive
clinical interventions for 6 to 12 weeks of individual or group coun-
seling led by professionals are generally more successful than self-
help1). Combining two or more methods for smoking cessation includ-
ing pharmacologic and non-pharmacologic therapies may also pro-
duce bigger success10). 
Pharmacological interventions are most effective when combine
with behavioral interventions, so most studies evaluating the use of
pharmacotherapy generally incorporated at least limited behavioral
therapy within the study protocol11). In this study, a combination of
both behavioural and pharmacologic therapies was applied to aid the
smokers quit, with the intention-to-treat method. Intention-to-treat
(ITT) is an important strategy to treat smokers in any clinical trials
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involving smoking cessation, for the analysis of randomized con-
trolled trials that compares patients in the groups to which they were
originally randomly assigned12).
In this study, adverse events reports were used to assess safety of
the herbal medication at any time point. No mortality case happened
throughout the study. Two subjects were hospitalized during the study
in two separated cases, but were not related to study medication. As
Viva QS® was developed from twelve herbs and contained various
ingredients; the tolerable adverse events suggested the herbs used in
the medication might not be harmful to be taken. However more
researches should be done to study the each of the herbs involved. 
Withdrawal symptoms reported were assessed using modified
version of revised Minnesota withdrawal scale (MNWS-R)4). Each
symptom was rated from 0 (absent) to 4 (severe). No significant dif-
ference was found between groups; concluded that Viva QS® is not
effective to reduce withdrawal symptoms. Initially, results were
unable to suggest Viva QS® is helpful to reduce craving or any other
withdrawal symptoms. For analysis, the mean symptoms score were
compared between withdrawals at week 2 and week 5, to assess the
severity of withdrawal symptoms at the early stage of quitting (week
2) and after 5 weeks of quitting. Reduction in mean symptoms was
found in both groups; results were concordance as in other previous
studies and theories that withdrawal symptoms usually will be over-
come by the subjects after 4 to 5 weeks of quitting13,14).
There are several limitations in this study. The study population
were mostly middle-aged Malay males, thus findings may not be gen-
eralized to other populations of smokers. Furthermore, subjects were
recruited from those who were motivated and voluntarily to quit,
which limits the generalization, but does represent the group of
smokers for whom pharmacotherapy may be most appropriate. 
Self-reported smoking status at all time points were not verified
except during final follow-up at week 24; thus results were unable to
be verified biochemically at other times. We estimated medication
compliance by self-reports and therefore could not be certain that
subjects assigned to receive Viva QS® actually took the medication
as directed. To avoid confusion, the significant differences in quit
rates were observed at all time points, and assumed that Viva QS®
was being taken as directed. 
This study was not initially designed to detect chemically which
components among the twelve herbs of Viva QS® contributed to the ces-
sation effect, but was designed to compare the overall effectiveness of
the medication as a whole and not to distinguish among the components. 
To strengthen the study, future research should be done to inves-
tigate the pharmacotherapy and therapeutic effects of the combina-
tion of the herbs in Viva QS® in details. Further studies could inves-
tigate the relative benefit of each component in Viva QS® and to find
the main component contributes to the cessation effect. Another issue
is regarding weight gain problem after cessation. Thus, future study
should investigate if Viva QS® is also effective to help quitters man-
aging problem with weight gain.
CONCLUSIONS
Viva QS® is effective and safe to be used as an aid for smoking ces-
sation in adult smokers, but further studies should be done to confirm the
results in other population samples, such as adolescents and elderly.
ACKNOWLEDGEMENT
The authors wish to thank Mr Lee Jae Hyung from Viva and
Revival Sdn. Bhd. for funding this study and International Islamic
University Malaysia (IIUM) for allowing this study to be conducted.
The authors also would like to express sincere gratitude to Dr.
Norsayani Yaakob from Petronas Gas Berhad and Dr. Wan Suzaidi
Wan Sulaiman from Optimal Chemical (Malaysia) Sdn. Bhd. for
helping throughout the study. 
REFERENCES
1) Rantucci M. Nicotine addiction. In C. Repchinsky and C. LeBlanc (Eds.), Patient self-
care: helping patients make therapeutic choices (pp. 97-113). Ottawa: Canadian
Pharmacist Association, 2002.
2) Report of the Third National Health and Morbidity Survey. Ministry of Health
Malaysia, 2006.
3) Abdul Aziz Abdullah, Ahmad Rasidi M. Saring, Dass RP, Dewi A. The efficacy of Viva
Capsule in suppressing opiate withdrawal symptoms: a double blind placebo controlled
study. Project report, Department of Psychiatry, Kuala Lumpur Hospital, 1993.
4) Hughes J, Hatsukami D. (n.d.). Minnesota Nicotine Withdrawal Scale - Revised
(MNWS-R). Retrieved December 12, 2008. http://www.uvm.edu/~hbpl/.
5) Jarvis MJ, Tunstall-Pedoe H, Feyerebend C, Vesey C, Saloojee Y. Comparisons of
tests used to distinguish smokers from non-smokers. Am J Public Health 1987;
77(11): 1435-1438. 
6) Montalto NJ, Wells WO. Validation of self-reported smoking status using saliva coti-
nine: a rapid semiquantitative dipstick method. Cancer Epidemiol Biomarkers Prev
2007; 16(9): 1858-1862.
7) Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. (2006). Effect
of maintenance therapy with Varenicline on smoking cessation. JAMA 2006; 296: 64-71.
8) Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a
randomized trial. Arch Intern Med 2004; 164: 1797-1803.
9) Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Gong J, Williams KE,
Billing CB, Reeves KR. (2006). Efficacy of Varenicline, an α4β2 nicotinic acetyl-
choline receptor partial agonist vs. placebo or sustained-release bupropion for smok-
ing cessation: a randomized controlled trial. JAMA 2006; 296: 56-63. 
10) Hughes JR. (2008). An algorithm for choosing among smoking cessation treatments. J
Subst Abuse Treat 2008; 34 (4): 426-432.
11) Koltyar M, Hatsukami DK. Managing smoking cessation. J Dent Educ 2002; 66 (9):
1061-1073.
12) Hollis S, Campbell F. What is meant by intention-to-treat analysis? Survey of pub-
lished randomized controlled trials. BMJ 1999; 319: 670-674.
13) Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. (2002). Sustained-release
bupropion for smoking cessation in African Americans: a randomized controlled trial.
JAMA 2002; 288(4): 468-474. 
14) McClernon FJ, Westman EC, Rose JE. The effects of controlled deep breathing on
smoking withdrawal symptoms in dependent smokers. Addict Behav 2004; 4: 765-772.
Zaswiza M. N. et al. 193
